Client news

A&O Shearman advises on Recordati financing for the acquisition of the global rights to Enjaymo

Published Date
Dec 23 2024
Recordati S.p.A., an international pharmaceutical group listed on the Italian Stock Exchange, subscribed a mid to long term financing for the acquisition of the global rights to Enjaymo® from Sanofi, the transaction successfully completed at the end of November. A&O Shearman advised the pool of financial institutions granting the financing.

Enjaymo® (sutimlimab) is a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder. Enjaymo® generated approximately EUR100 million in revenue in the twelve months at August 2024.

The A&O Shearman team advising the pool of lenders was led by partner Stefano Sennhauser and comprised associate Valentina Calò and trainee Laura Margelli, with counsel Elia Ferdinando Clarizia advising on tax-related matters.

Related capabilities